[Combination therapy of large amount of carboquone and OK-432 for unresectable lung cancer].
The combination of 1 KE/day of OK-432 (everyday) and 10 mg/day of Carboquone (once a week) had been administered for three weeks to 18 cases of the patients with unresectable lung cancer. The response rate was 50% in the patients whose diameters of tumors could be measured. These results might be provided by the fact that the large dose administration of Carboquone became possible with simultaneous administration of OK-432, which might have an activating effect of bone marrow function; consequently, original properties of alkylating agent could be utilized in this therapy. Leukopenia, (leukocyte counts: less than 3,000) was observed in 10 out of 18 cases (55.6%) at one week after administration of the drugs, and in all but one case leukopenia was recovered after 4 weeks of the administration. No other severe side effects were observed.
D000368:Aged; D001389:Azirines / Q000008:administration & dosage*; D001688:Biological Products / Q000008:administration & dosage*; D002225:Carbazilquinone / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D006801:Humans; D007962:Leukocytes / Q000187:drug effects; D008175:Lung Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D010844:Picibanil / Q000008:administration & dosage*
D001389:Azirines; D001688:Biological Products; D002225:Carbazilquinone; D010844:Picibanil